The 2015 ICER Policy Summit convened an influential group of evidence policy leaders from insurers, pharmacy benefit management firms, and life science companies to discuss indication-specific pricing (ISP) of biopharmaceuticals and to explore the opportunities and challenges of ISP in the US health care system.

Date of review: December 2015

For more information, please contact

Final Documents

Below you will find the final documents from the policy paper review process: